{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T18:30:01Z","timestamp":1772130601201,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"DOI":"10.1186\/s13195-025-01814-7","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T09:07:39Z","timestamp":1752570459000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dual risk of anticholinergic burden and CSF alzheimer\u2019s biomarkers in older patients: a mortality follow-up study from daily medical practice"],"prefix":"10.1186","volume":"17","author":[{"given":"Th\u00e9odore","family":"Decaix","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Dumurgier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Cognat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl","family":"G\u00f6tze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Mouton-Liger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Hugon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elodie","family":"Bouaziz-Amar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthieu","family":"Lilamand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Paquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"1814_CR1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s40520-015-0359-7","volume":"28","author":"A Collamati","year":"2016","unstructured":"Collamati A, Martone AM, Poscia A, et al. Anticholinergic drugs and negative outcomes in the older population: from biological plausibility to clinical evidence. Aging Clin Exp Res. 2016;28:25\u201335. https:\/\/doi.org\/10.1007\/s40520-015-0359-7.","journal-title":"Aging Clin Exp Res"},{"key":"1814_CR2","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1111\/bcp.15727","volume":"89","author":"SN Hilmer","year":"2023","unstructured":"Hilmer SN, Lo S, Kelly PJ, et al. Towards optimizing hospitalized older adults\u2019 medications (TO HOME): multi-centre study of medication use and outcomes in routine care. Br J Clin Pharmacol. 2023;89:2508\u201318. https:\/\/doi.org\/10.1111\/bcp.15727.","journal-title":"Br J Clin Pharmacol"},{"key":"1814_CR3","doi-asserted-by":"publisher","first-page":"CD015196","DOI":"10.1002\/14651858.CD015196.pub2","volume":"8","author":"M Taylor-Rowan","year":"2022","unstructured":"Taylor-Rowan M, Kraia O, Kolliopoulou C, et al. Anticholinergic burden for prediction of cognitive decline or neuropsychiatric symptoms in older adults with mild cognitive impairment or dementia. Cochrane Database Syst Rev. 2022;8:CD015196. https:\/\/doi.org\/10.1002\/14651858.CD015196.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"1814_CR4","doi-asserted-by":"publisher","first-page":"CD013540","DOI":"10.1002\/14651858.CD013540.pub2","volume":"5","author":"M Taylor-Rowan","year":"2021","unstructured":"Taylor-Rowan M, Edwards S, Noel-Storr AH, et al. Anticholinergic burden (prognostic factor) for prediction of dementia or cognitive decline in older adults with no known cognitive syndrome. Cochrane Database Syst Rev. 2021;5:CD013540. https:\/\/doi.org\/10.1002\/14651858.CD013540.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"1814_CR5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.archger.2014.01.006","volume":"59","author":"AC Kidd","year":"2014","unstructured":"Kidd AC, Musonda P, Soiza RL, et al. The relationship between total anticholinergic burden (ACB) and early in-patient hospital mortality and length of stay in the oldest old aged 90 years and over admitted with an acute illness. Arch Gerontol Geriatr. 2014;59:155\u201361. https:\/\/doi.org\/10.1016\/j.archger.2014.01.006.","journal-title":"Arch Gerontol Geriatr"},{"key":"1814_CR6","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00228-019-02795-x","volume":"76","author":"S Ali","year":"2020","unstructured":"Ali S, Peterson GM, Bereznicki LR, Salahudeen MS. Association between anticholinergic drug burden and mortality in older people: a systematic review. Eur J Clin Pharmacol. 2020;76:319\u201335. https:\/\/doi.org\/10.1007\/s00228-019-02795-x.","journal-title":"Eur J Clin Pharmacol"},{"key":"1814_CR7","doi-asserted-by":"publisher","first-page":"e406","DOI":"10.1016\/S2666-7568(24)00061-8","volume":"5","author":"BCM Stephan","year":"2024","unstructured":"Stephan BCM, Cochrane L, Kafadar AH, et al. Population attributable fractions of modifiable risk factors for dementia: a systematic review and meta-analysis. Lancet Healthy Longev. 2024;5:e406\u201321. https:\/\/doi.org\/10.1016\/S2666-7568(24)00061-8.","journal-title":"Lancet Healthy Longev"},{"key":"1814_CR8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13195-023-01220-x","volume":"15","author":"M R\u00e9gy","year":"2023","unstructured":"R\u00e9gy M, Dugravot A, Sabia S, et al. Association between ATN profiles and mortality in a clinical cohort of patients with cognitive disorders. Alzheimers Res Ther. 2023;15:77. https:\/\/doi.org\/10.1186\/s13195-023-01220-x.","journal-title":"Alzheimers Res Ther"},{"key":"1814_CR9","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3233\/JAD-220448","volume":"90","author":"A Vipin","year":"2022","unstructured":"Vipin A, Koh CL, Wong BYX, et al. Amyloid-tau-neurodegeneration profiles and longitudinal cognition in sporadic young-onset dementia. J Alzheimers Dis. 2022;90:543\u201351. https:\/\/doi.org\/10.3233\/JAD-220448.","journal-title":"J Alzheimers Dis"},{"key":"1814_CR10","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1002\/alz.12491","volume":"17","author":"A Ezzati","year":"2021","unstructured":"Ezzati A, Abdulkadir A, Jack CR Jr, et al. Predictive value of ATN biomarker profiles in estimating disease progression in alzheimer\u2019s disease dementia. Alzheimers Dement. 2021;17:1855\u201367. https:\/\/doi.org\/10.1002\/alz.12491.","journal-title":"Alzheimers Dement"},{"key":"1814_CR11","doi-asserted-by":"publisher","first-page":"100009","DOI":"10.1016\/j.tjpad.2024.100009","volume":"12","author":"T Decaix","year":"2025","unstructured":"Decaix T, Mouton-Liger F, Dumurgier J, et al. Usefulness of cerebrospinal fluid alzheimer\u2019s disease biomarkers in older patients: evidence from a National multicenter prospective study. J Prev Alzheimers Dis. 2025;12:100009. https:\/\/doi.org\/10.1016\/j.tjpad.2024.100009.","journal-title":"J Prev Alzheimers Dis"},{"key":"1814_CR12","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/j.jamda.2023.08.001","volume":"24","author":"Y Qiu","year":"2023","unstructured":"Qiu Y, Li G, Zheng L, et al. Relationship between cognitive frailty and mortality in older adults: a systematic review and meta-analysis. J Am Med Dir Assoc. 2023;24:1637\u2013e448. https:\/\/doi.org\/10.1016\/j.jamda.2023.08.001.","journal-title":"J Am Med Dir Assoc"},{"key":"1814_CR13","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Volume 5. Washington, D.C.: American Psychiatric Association; 2013."},{"key":"1814_CR14","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s association workgroups on diagnostic guidelines for alzheimer\u2019s disease. Alzheimers Dement. 2011;7:263\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005.","journal-title":"Alzheimers Dement"},{"key":"1814_CR15","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2217\/1745509X.4.3.311","volume":"4","author":"M Boustani","year":"2008","unstructured":"Boustani M, Campbell N, Munger S, Maidment I, Fox C. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health. 2008;4:311\u201320. https:\/\/doi.org\/10.2217\/1745509X.4.3.311.","journal-title":"Aging Health"},{"key":"1814_CR16","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00228-020-02994-x","volume":"77","author":"A Lisibach","year":"2021","unstructured":"Lisibach A, Benelli V, Ceppi MG, Waldner-Knogler K, Csajka C, Lutters M. Quality of anticholinergic burden scales and their impact on clinical outcomes: a systematic review. Eur J Clin Pharmacol. 2021;77:147\u201362. https:\/\/doi.org\/10.1007\/s00228-020-02994-x.","journal-title":"Eur J Clin Pharmacol"},{"key":"1814_CR17","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","volume":"15","author":"FE Harrell Jr","year":"1996","unstructured":"Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361\u201387. https:\/\/doi.org\/10.1002\/(SICI)1097-0258(19960229)15:4%3C;361::AID-SIM168%3E;3.0.CO;2-4.","journal-title":"Stat Med"},{"key":"1814_CR18","doi-asserted-by":"publisher","first-page":"e1262","DOI":"10.1212\/WNL.0000000000200048","volume":"98","author":"M van de Beek","year":"2022","unstructured":"van de Beek M, Ooms FAH, Ebenau JL, et al. Association of the ATN research framework with clinical profile, cognitive decline, and mortality in patients with dementia with lewy bodies. Neurology. 2022;98:e1262\u201372. https:\/\/doi.org\/10.1212\/WNL.0000000000200048.","journal-title":"Neurology"},{"key":"1814_CR19","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.nbd.2010.07.007","volume":"40","author":"J Dumurgier","year":"2010","unstructured":"Dumurgier J, Paquet C, Benisty S, et al. Inverse association between CSF A\u03b2 42 levels and years of education in mild form of alzheimer\u2019s disease: the cognitive reserve theory. Neurobiol Dis. 2010;40:456\u20139. https:\/\/doi.org\/10.1016\/j.nbd.2010.07.007.","journal-title":"Neurobiol Dis"},{"key":"1814_CR20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13195-019-0481-4","volume":"11","author":"A Boumenir","year":"2019","unstructured":"Boumenir A, Cognat E, Sabia S, et al. CSF level of \u03b2-amyloid peptide predicts mortality in alzheimer\u2019s disease. Alzheimers Res Ther. 2019;11:29. https:\/\/doi.org\/10.1186\/s13195-019-0481-4.","journal-title":"Alzheimers Res Ther"},{"key":"1814_CR21","doi-asserted-by":"publisher","first-page":"e1920","DOI":"10.1212\/WNL.0000000000005549","volume":"90","author":"OL Lopez","year":"2018","unstructured":"Lopez OL, Becker JT, Chang Y, et al. Amyloid deposition and brain structure as long-term predictors of MCI, dementia, and mortality. Neurology. 2018;90:e1920\u20138. https:\/\/doi.org\/10.1212\/WNL.0000000000005549.","journal-title":"Neurology"},{"key":"1814_CR22","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1159\/000499066","volume":"47","author":"M Ribbe","year":"2019","unstructured":"Ribbe M, Kern S, Borjesson Hansson A, et al. Amyloid beta42 and total Tau levels in cerebrospinal fuid associate with survival in an 85-year-old population-based cohort followed until death. Dement Geriatr Cogn Disord. 2019;47:114\u201324. https:\/\/doi.org\/10.1159\/000499066.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"1814_CR23","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/bcpt.13184","volume":"124","author":"YM Ah","year":"2019","unstructured":"Ah YM, Suh Y, Jun K, Hwang S, Lee JY. Effect of anticholinergic burden on treatment modification, delirium and mortality in newly diagnosed dementia patients starting a cholinesterase inhibitor: a population-based study. Basic Clin Pharmacol Toxicol. 2019;124:741\u20138. https:\/\/doi.org\/10.1111\/bcpt.13184.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"1814_CR24","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3233\/JAD-170265","volume":"60","author":"AJ Cross","year":"2017","unstructured":"Cross AJ, George J, Woodward MC, et al. Potentially inappropriate medication, anticholinergic burden, and mortality in people attending memory clinics. J Alzheimers Dis. 2017;60:349\u201358. https:\/\/doi.org\/10.3233\/JAD-170265.","journal-title":"J Alzheimers Dis"},{"key":"1814_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.maturitas.2021.06.004","volume":"151","author":"K Wang","year":"2021","unstructured":"Wang K, Alan J, Page AT, Dimopoulos E, Etherton-Beer C. Anticholinergics and clinical outcomes amongst people with pre-existing dementia: a systematic review. Maturitas. 2021;151:1\u201314. https:\/\/doi.org\/10.1016\/j.maturitas.2021.06.004.","journal-title":"Maturitas"},{"key":"1814_CR26","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1093\/brain\/awy132","volume":"141","author":"H Hampel","year":"2018","unstructured":"Hampel H, Mesulam MM, Cuello AC, et al. The cholinergic system in the pathophysiology and treatment of alzheimer\u2019s disease. Brain. 2018;141:1917\u201333. https:\/\/doi.org\/10.1093\/brain\/awy132.","journal-title":"Brain"},{"key":"1814_CR27","doi-asserted-by":"publisher","first-page":"2","DOI":"10.14283\/jpad.2018.43","volume":"6","author":"H Hampel","year":"2019","unstructured":"Hampel H, Mesulam MM, Cuello AC, et al. Revisiting the cholinergic hypothesis in alzheimer\u2019s disease: emerging evidence from translational and clinical research. J Prev Alzheimers Dis. 2019;6:2\u201315. https:\/\/doi.org\/10.14283\/jpad.2018.43.","journal-title":"J Prev Alzheimers Dis"},{"key":"1814_CR28","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00401-023-02616-7","volume":"146","author":"JM Judd","year":"2023","unstructured":"Judd JM, Jasbi P, Winslow W, et al. Inflammation and the pathological progression of alzheimer\u2019s disease are associated with low Circulating choline levels. Acta Neuropathol. 2023;146:565\u201383. https:\/\/doi.org\/10.1007\/s00401-023-02616-7.","journal-title":"Acta Neuropathol"},{"key":"1814_CR29","doi-asserted-by":"publisher","first-page":"e2313","DOI":"10.1212\/WNL.0000000000201161","volume":"99","author":"C Truong","year":"2022","unstructured":"Truong C, Recto C, Lafont C, Canoui-Poitrine F, Belmin JB, Lafuente-Lafuente C. Effect of cholinesterase inhibitors on mortality in patients with dementia: a systematic review of randomized and nonrandomized trials. Neurology. 2022;99:e2313\u201325. https:\/\/doi.org\/10.1212\/WNL.0000000000201161.","journal-title":"Neurology"},{"key":"1814_CR30","doi-asserted-by":"publisher","unstructured":"2024 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2024;20:3708\u2013821. https:\/\/doi.org\/10.1002\/alz.13809","DOI":"10.1002\/alz.13809"},{"key":"1814_CR31","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4103\/1673-5374.264445","volume":"15","author":"B Mdawar","year":"2020","unstructured":"Mdawar B, Ghossoub E, Khoury R. Selective serotonin reuptake inhibitors and alzheimer\u2019s disease. Neural Regen Res. 2020;15:41\u20136. https:\/\/doi.org\/10.4103\/1673-5374.264445.","journal-title":"Neural Regen Res"},{"key":"1814_CR32","doi-asserted-by":"publisher","first-page":"afad176","DOI":"10.1093\/ageing\/afad176","volume":"52","author":"E Braithwaite","year":"2023","unstructured":"Braithwaite E, Todd OM, Atkin A, et al. Interventions for reducing anticholinergic medication burden in older adults-a systematic review and meta-analysis. Age Ageing. 2023;52:afad176. https:\/\/doi.org\/10.1093\/ageing\/afad176.","journal-title":"Age Ageing"},{"key":"1814_CR33","doi-asserted-by":"publisher","first-page":"afaf014","DOI":"10.1093\/ageing\/afaf014","volume":"54","author":"S McGettigan","year":"2025","unstructured":"McGettigan S, Curtin D, O\u2019Mahony D. Deprescribing in cognitively vulnerable older people: development and validation of STOPPCog criteria. Age Ageing. 2025;54:afaf014. https:\/\/doi.org\/10.1093\/ageing\/afaf014.","journal-title":"Age Ageing"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01814-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-025-01814-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01814-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T10:25:46Z","timestamp":1757240746000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-025-01814-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1814"],"URL":"https:\/\/doi.org\/10.1186\/s13195-025-01814-7","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"assertion":[{"value":"15 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants received both oral and written information regarding the opportunity to provide additional blood and CSF samples for further research, as outlined in the BioCogBank\u00a9 protocol. Additionally, all participants consented to the anonymous use of their clinical data and the results of their CSF analyses. The study was approved by the local Ethics Committee (Comit\u00e9 d\u2019\u00c9valuation et d\u2019\u00c9thique pour la Recherche Paris Nord, Institutional Review Board 00006477, ref 16\u2009\u2212\u2009004) and the Commission Nationale Informatique et Libert\u00e9s. This study was conducted in accordance with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"162"}}